This article describes discovery of a novel and new class of cholinesterase inhibitors as potential therapeutics
for Alzheimer’s disease. A series of novel isoalloxazine derivatives were synthesized and biologically
evaluated for their potential inhibitory outcome for both acetylcholinesterase (AChE) and
butyrylcholinesterase (BuChE). These compounds exhibited high activity against both the enzymes
AChE as well as BuChE. Of the synthesized compounds, the most potent isoalloxazine derivatives (7m
and 7q) showed IC50 values of 4.72 lM and 5.22 lM respectively against AChE; and, 6.98 lM and
5.29 lM respectively against BuChE. These two compounds were further evaluated for their
anti-aggregatory activity for b-amyloid (Ab) in presence and absence of AChE by performing
Thioflavin-T (ThT) assay and Congo red (CR) binding assay. In order to evaluate cytotoxic profile of these
two potential compounds, cell viability assay of SH-SY5Y human neuroblastoma cells was performed.
Further, to understand the binding behavior of these two compounds with AChE and BuChE enzymes,
docking studies have been reported.